109 related articles for article (PubMed ID: 15613062)
1. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
Abellán J; Leal M; Hernández-Menárguez F; García-Galbis JA; Martínez-Pastor A; de Vinuesa SG; Luño J
Kidney Int Suppl; 2005 Jan; (93):S20-4. PubMed ID: 15613062
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
3. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Sharma AM; Wagner T; Marsalek P
J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of moxonidine in mild to moderate hypertension.
Jain S; Malhotra P; Kumari S; Varma S
J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
[TBL] [Abstract][Full Text] [Related]
5. Selective imidazoline agonist moxonidine in obese hypertensive patients.
Sanjuliani AF; de Abreu VG; Francischetti EA
Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
[TBL] [Abstract][Full Text] [Related]
6. The effect of moxonidine on endothelial dysfunction in metabolic syndrome.
Topal E; Cikim AS; Cikim K; Temel I; Ozdemir R
Am J Cardiovasc Drugs; 2006; 6(5):343-8. PubMed ID: 17083269
[TBL] [Abstract][Full Text] [Related]
7. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
Haenni A; Lithell H
J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
[TBL] [Abstract][Full Text] [Related]
8. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.
Jacob S; Klimm HJ; Rett K; Helsberg K; Häring HU; Gödicke J
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):315-22. PubMed ID: 15216449
[TBL] [Abstract][Full Text] [Related]
9. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
Masajtis-Zagajewska A; Majer J; Nowicki M
Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
[TBL] [Abstract][Full Text] [Related]
10. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
11. Use of moxonidine in elderly patients with resistant hypertension.
Martin U; Hill C; O' Mahony D
J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
13. Effective antihypertensive therapy: blood pressure control with moxonidine.
Prichard BN; Graham BR
J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
[TBL] [Abstract][Full Text] [Related]
14. Moxonidine: a review of its use in essential hypertension.
Fenton C; Keating GM; Lyseng-Williamson KA
Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE
J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764
[TBL] [Abstract][Full Text] [Related]
16. [Pathogenetic role of moxonidine in the treatment of hypertension in postmenopausal women].
Podzolkov VI; Bragina AE; Makolkin VI
Kardiologiia; 2002; 42(11):32-5. PubMed ID: 12494033
[TBL] [Abstract][Full Text] [Related]
17. Comparison of moxonidine and clonidine HCl in treating patients with hypertension.
Plänitz V
J Clin Pharmacol; 1987 Jan; 27(1):46-51. PubMed ID: 3316304
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
Lewin AJ; Weir MR
Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
[TBL] [Abstract][Full Text] [Related]
19. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.
Ebinç H; Ozkurt ZN; Ebinç FA; Ucardag D; Caglayan O; Yilmaz M
J Int Med Res; 2008; 36(1):80-7. PubMed ID: 18230271
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)].
Krupicka J; Soucek M; Chroust K
Vnitr Lek; 2011 Jun; 57(6):541-5. PubMed ID: 21751539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
